M ore than half of ischemic stroke patients who are treated with IV recombinant tissue-type plasminogen activator (rtPA) remain disabled at 3 months. The reasons are many. The IV rtPA rate of recanalizing occluded arteries is not as high as we would like, especially for large arterial occlusions, which are opened only 30% to 40% of the time. 3–6 When rtPA does effectively lyse a thrombus, it is...

BACKGROUND Currently, the two most commonly used fibrinolytic agents in thrombolytic therapy are recombinant tissue plasminogen activator (rt-PA) and streptokinase (SK). Whereas SK has the advantage of substantially lower costs when compared to other agents, it is less effective than either rt-PA or related variants, has significant allergenic potential, lacks fibrin selectivity and causes tran...

Abstract Introduction The main function of the fibrinolytic system is to dissolve fibrin clots in circulation. This system is composed of inactive precursor plasminogen which can be converted into plasmin by the proteolytic enzymes like tissue-type plasminogen activator (tPA). Fibrinolytic properties can be found in a variety of medicine plants and they could effectively prevent cardiovascula...

After years of setbacks, the perspective of neuroprotective stroke therapy has revived in light of recent study results. We outline in this review how a neuroprotective candidate drug should be developed, beginning with a thorough preclinical evaluation according to the STAIR (Stroke Therapy Academic Industry Roundtable) criteria. Assessing the safety of the candidate drug in the relatively str...

Brooks NH, et al. ACC/AHA Guidelines for the management of patients with acute myocardial infarction. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocar-dial Infarction Study Group. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction: Myocardial Infarction Tri-Clini...

IT HAS been shown in experimental animals that the human fibrinolytic enzyme (plasminogen activated with streptokinase) will dissolve fresh intravascular thrombi." Fibrinolytic agents are also undergoing an extensive clinical trial and the preliminary reports which have appeared*" have suggested that this type of therapy will be of value in the management of thrombo-embolic disorders. Variation...

OBJECTIVE Allium elburzense is an endemic plant of the family Amaryllidaceae that grows wild in northern Iran with some nutritional and medicinal applications. The present study was aimed to investigate the fibrinolytic and antioxidant effects of A. elburzense bulb extracts. MATERIALS AND METHODS Hydroalcoholic, aqueous, chloroformic and butanolic extracts were evaluated in this research. In ...

Thrombolytic therapy, which involves the administration of agents designed to increase fibrinolytic capacity, has been utilized in respiratory medicine for more than 50 years. A variety of agents have been used to effect thrombolysis, including urokinase plasminogen activator (uPA) and streptokinase. Tissue plasminogen activator (tPA) has also been used to effect thrombolysis. Both uPA and tPA ...

A considerable number of agents have been proposed as causing ligneous conjunctivitis. We report the first case to arise as a side effect of tranexamic acid (Cyclokapron), an anti-fibrinolytic drug used in the treatment of menorrhagia. In addition to the typical conjunctival changes our patient had lesions affecting the gingiva and the peritoneum the last causing considerable protein loss into ...